Jabil Inc Stock: AI-Driven Growth and Raised 2026 Outlook Signal Strong Momentum for Investors

Jabil Inc (ISIN: US4663131039) reports robust Q2 fiscal 2026 results with 23% revenue growth to $8.3 billion, lifts full-year guidance to $34 billion driven by AI infrastructure and healthcare, positioning shares for continued upside amid data center demand.

Jabil Inc shares have gained significant traction following the company's fiscal second-quarter 2026 earnings release in March 2026, which showcased 23% year-over-year revenue growth to $8.3 billion and adjusted EPS of $2.69, beating analyst expectations.

This performance, primarily fueled by its intelligent infrastructure segment now comprising half of total revenue, prompted Jabil to raise its full-year fiscal 2026 revenue outlook to $34 billion and EPS guidance to $12.25.

As of: 02.04.2026

By Elena Vargas, Senior Financial Editor at NorthStar Markets: Jabil Inc stands at the intersection of AI hardware manufacturing and healthcare innovation, powering critical supply chains for North American tech leaders.

Core Business Model and Strategic Shift

Jabil Inc operates as a global manufacturing services provider, specializing in electronics design, production, and supply chain solutions for diverse industries including technology, healthcare, and automotive.

The company's business model centers on end-to-end solutions, from product design to high-volume manufacturing and logistics, serving hyperscalers and enterprise clients seeking scalable production capabilities.

Recent strategic shifts emphasize higher-margin segments like AI infrastructure and healthcare devices, reducing reliance on cyclical markets such as electric vehicles and renewables.

This pivot allows Jabil to capture value in fast-growing areas, with intelligent infrastructure now driving half of its revenue and demonstrating 46% annual growth projections for fiscal 2026.

Recent Financial Performance and Guidance

In fiscal Q2 2026, Jabil achieved net revenue of approximately $8.3 billion, a 23% increase from the prior year, with adjusted operating margins improving due to favorable product mix and cost controls.

Adjusted EPS reached $2.69, surpassing consensus estimates by $0.18, while the intelligent infrastructure segment saw operating margin expansion of 40 basis points.

Management raised full-year fiscal 2026 revenue guidance to $34 billion, reflecting confidence in sustained demand, and projected AI-related revenue to grow 46% to $13.1 billion.

Third-quarter guidance points to net revenue between $8.10 billion and $8.90 billion, with GAAP operating income of $398 million to $458 million and diluted EPS of $2.36 to $2.76, signaling continued momentum.

These figures underscore Jabil's ability to execute amid sector tailwinds, with capacity utilization at 75% expected to rise to 80%, supporting margin expansion toward over 6%.

AI Infrastructure as Key Growth Driver

Jabil's exposure to AI data centers positions it as a vital supplier in the supply chain for hyperscalers building out infrastructure for generative AI and cloud computing.

The intelligent infrastructure division, encompassing cooling solutions, photonics, and server components, now accounts for 50% of revenue and is forecasted for 46% growth in fiscal 2026.

Discussions with a third hyperscaler customer for data center solutions could materialize into fiscal 2027 revenue, further bolstering the segment's trajectory.

This focus aligns with surging global demand for AI hardware, where Jabil's manufacturing expertise in high-density, power-efficient components provides a competitive edge.

Analysts note the 23% revenue surge and 39% EPS growth validate the AI pivot, with recent price target upgrades from firms like Stifel to $290 reflecting optimism.

Healthcare and Diversification Opportunities

Beyond AI, Jabil's healthcare segment is gaining prominence, particularly through manufacturing injector pens for GLP-1 weight-loss drugs, contributing to the raised 2026 outlook.

This exposure diversifies revenue streams, offsetting volatility in renewables and EVs, as healthcare demand remains resilient.

Jabil's capabilities in precision medical devices and drug delivery systems position it to benefit from ongoing innovation in pharmaceuticals and telemedicine.

The combination of steady healthcare growth and AI acceleration enhances earnings stability, making Jabil more attractive for long-term portfolios.

Relevance for North American Investors

For North American investors, Jabil offers exposure to the AI boom without direct reliance on volatile semiconductor stocks, trading on the NYSE under ticker JBL in USD.

The company's U.S.-based operations and supply chain proximity support domestic manufacturing trends, potentially benefiting from policy incentives.

With a consensus Moderate Buy rating and average price targets around $283, shares present upside potential amid broader tech sector strength.

Institutional interest remains strong, as evidenced by recent stake increases from funds like Meyer Handelman, holding positions valued in the millions.

Jabil's return on equity above 80% and net margins around 2.5% highlight efficient capital use, appealing to value-oriented investors seeking growth.

Risks and Key Factors to Monitor

While momentum is strong, investors should watch tariff and trade uncertainties, which could impact customer demand and inventory levels.

Execution risks in ramping new programs, including healthcare injector production and hyperscaler deals, remain critical swing factors.

Capacity constraints, with utilization targeted at 80%, could limit growth if demand exceeds expectations.

Broader market volatility in AI-related stocks and shifts in EV/renewables demand warrant vigilance.

North American investors should track upcoming Q3 results for confirmation of guidance, alongside macroeconomic indicators affecting tech spending.

Overall, Jabil's validated strategy and recent beats make it a stock to watch, balancing growth prospects with manageable risks.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.